AUS
NZ
UK
CA
USA
IND
Healt
4DMedical’s Next Chapter: Can Innovation Reshape Market Confidence?
March 10, 2026 05:38 PM AEDT| By SamHealthcare technology companies continue shaping Australia’s market landscape as innovation in respiratory imaging and medical diagnostics attracts attention for its potential role in improving clinical insights and treatment pathways.
Lung Imaging Story: What’s Next for 4DMedical?
March 10, 2026 05:19 PM AEDT| By Sam4DMedical’s latest financial update highlights stable revenue but rising losses, shifting investor attention toward technology adoption, funding resilience, and the evolving role of advanced lung imaging in respiratory healthcare innovation.
Imugene Azer-Cel Trial Sparks Hope in Blood Cancer Fight
March 10, 2026 04:30 PM AEDT| By SamImugene’s azer-cel immunotherapy gains attention after a remission case in its clinical trial. The CAR-T therapy program is advancing research for difficult-to-treat blood cancers across global study sites.
Dimerix Advances Within the All Ordinaries Biotech Space
March 10, 2026 02:00 PM AEDT| By SamDimerix completes adult dosing in its ACTION3 phase trial, with enrolment surpassing target, reinforcing its progress within the All Ordinaries biotech sector.
Why Did the ASX Healthcare Sector Shift Midday Within the ASX 200 Market?
March 10, 2026 01:45 PM AEDT| By SamAustralia’s healthcare sector recorded varied midday activity within the ASX market as biotechnology, pharmaceutical, and medical technology companies remained active across benchmark indices.
CSL Limited Movement Draws Attention in ASX 200 Healthcare Segment
March 10, 2026 01:12 PM AEDT| By SamCSL Limited’s recent movement highlights how earnings updates can influence healthcare sector sentiment within the ASX 300 and ASX All Ords.
ASX 200 Healthcare Stock Surges Amid Market Rotation
March 10, 2026 12:56 PM AEDT| By SamAn ASX 200 healthcare stock climbs strongly as sector rotation supports defensive names within the ASX 300 and All Ordinaries.
Neuren Pharmaceuticals Slides Amid ASX 300 Healthcare Volatility
March 10, 2026 12:27 PM AEDT| By SamNeuren Pharmaceuticals declines following earnings, reflecting valuation recalibration within the ASX 300 and ASX All Ords healthcare segment.
Nanosonics Advances CORIS Platform After US Clearance
March 09, 2026 07:21 PM AEDT| By SamNanosonics advances its CORIS platform after US regulatory clearance expands endoscope compatibility. The development highlights progress in infection-prevention technology and strengthens the company’s position in hospital sterilisation innovation.
Clinuvel Earnings Insight: What It Signals for ASX Healthcare
March 09, 2026 03:59 PM AEDT| By SamClinuvel Pharmaceuticals earnings update has triggered fresh valuation discussion across Australia’s biotechnology sector, highlighting product concentration dynamics and the evolving outlook for specialised healthcare innovation.
Clinuvel Pharmaceuticals Strengthens Profile Within ASX All Ords
March 09, 2026 01:16 PM AEDT| By SamClinuvel Pharmaceuticals maintains its position within the ASX All Ords, reflecting its role in Australia’s biotechnology and healthcare sector landscape.
ASX Market Update: Is Telix Advancing Its AI Imaging Strategy Within the ASX 200?
March 06, 2026 06:36 PM AEDT| By SamTelix advances AI-driven prostate imaging and outlines revenue expectations, reinforcing its role in healthcare innovation within the ASX 200.
HitIQ Seeks ASX Quotation for New Shares and Options
March 06, 2026 04:45 PM AEDT| By SamAn Australian sports technology company expands its capital structure through quotation of new securities, supporting development of wearable monitoring devices and advanced analytics for improved athlete safety and performance insights.
HitIQ Director Fee Share Move Signals Governance Strategy
March 06, 2026 04:26 PM AEDT| By SamA governance update highlights how an Australian technology company manages capital structure while advancing innovation in sports safety monitoring, reflecting broader trends shaping emerging businesses across the exchange.
Recce Pharmaceuticals Ltd Weakens as All Ordinaries Healthcare Volatility Rises
March 06, 2026 03:50 PM AEDT| By SamRecce Pharmaceuticals Ltd declines despite revenue expansion, reflecting widened losses and shifting sentiment within the All Ordinaries healthcare segment.
PYC Therapeutics Update Sparks ASX Market Interest
March 06, 2026 11:25 AM AEDT| By SamHighlights,PYC Therapeutics expands its quoted share base on the Australian market,Additional securities may influence liquidity and trading participation,Development-focused biotechnology activity continues to attract attention,PYC Therapeutics expa...
Rhythm Biosciences Share Update Draws Attention Across ASX Market
March 06, 2026 11:12 AM AEDT| By SamRhythm Biosciences progresses quotation of additional ordinary shares, illustrating capital market engagement and the evolving role of biotechnology firms within Australia’s healthcare innovation ecosystem.
ASX 200 Spotlight: Telix Drives Cancer AI Push
March 06, 2026 01:24 AM AEDT| By SamHighlights,Telix expands precision oncology pipeline across major cancers,AI integration reshapes radiopharmaceutical discovery strategy,Global commercial rollout strengthens Australian biotech presence,Telix Pharmaceuticals Limited (ASX:TLX) is an A...
Mesoblast ASX 100 Index Outlook After Earnings Update
March 03, 2026 05:29 PM AEDT| By SamHighlights,Mesoblast’s earnings update sharpens market focus on valuation outlook.,Ryoncil regulatory progress drives renewed sector attention.,Biotech sentiment shifts across the broader Australian share market.,Australia’s biotechnology landscape c...
ASX 200 Watch: High Volume Shakes Incannex Healthcare
March 03, 2026 11:12 AM AEDT| By SamA surge in trading activity around a clinical-stage healthcare company highlights how liquidity, sentiment and sector dynamics interact within Australia’s evolving biotechnology landscape.
Advertise your brand on Kalkine Media